Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Juni 2018 10:24 ET | Quelle: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
20. Juni 2018 07:20 ET | Quelle: InspireMD, Inc.

InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil

Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
18. Juni 2018 09:42 ET | Quelle: InspireMD, Inc.

InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery

Study results presented from 46 patients treated over two years with zero complicationsPresident of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of...
11. Juni 2018 09:53 ET | Quelle: InspireMD, Inc.

InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress

Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
30. Mai 2018 07:31 ET | Quelle: InspireMD, Inc.

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...
16. Mai 2018 08:12 ET | Quelle: InspireMD, Inc.

InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador

Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
07. Mai 2018 16:05 ET | Quelle: InspireMD, Inc.

InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018

Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
01. Mai 2018 07:00 ET | Quelle: InspireMD, Inc.

InspireMD Schedules First Quarter 2018 Earnings Conference Call

TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
30. April 2018 07:34 ET | Quelle: InspireMD, Inc.

InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam

TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
19. April 2018 07:00 ET | Quelle: InspireMD, Inc.

InspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland

TEL AVIV, ISRAEL, April 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...

Vorherige Seite

Nächste Seite